Literature DB >> 17559953

The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats.

David Feifel1, Gilia Melendez, Kristianne Priebe, Paul D Shilling.   

Abstract

We previously reported that vasopressin deficient Brattleboro (BRAT) rats exhibit deficits in prepulse inhibition (PPI) of the startle reflex that are consistent with PPI deficits exhibited by patients with schizophrenia and other neuropsychiatric disorders. Preliminary evidence indicates that this may be the basis of a predictive model for antipsychotic drug efficacy. Here we report the effects of acute and chronic administration of established and putative antipsychotics on these PPI deficits. BRAT rats, compared to their derivative strain, Long Evans rats, exhibited significantly decreased PPI and startle habituation consistent with patients with schizophrenia and other neuropsychiatric disorders. The second generation antipsychotics, risperidone and clozapine as well as a neurotensin agonist (PD149163) increased BRAT rat PPI, whereas saline, the typical antipsychotic, haloperidol, and a vasopressin analog (1-desamino-D-arginine vasopressin) did not. Similar to their effects in humans, chronic administration of antipsychotic drugs produced stronger effects than acute administration. These results further support the BRAT rat as a model of sensorimotor gating deficits with predictive validity for antipsychotics. The model appears to be able to differentiate first generation from second generation antipsychotics, identify putative antipsychotics with novel mechanisms (i.e., peptides) and reasonably model the therapeutic time course of antipsychotic drugs in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17559953     DOI: 10.1016/j.bbr.2007.04.020

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  20 in total

1.  Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Authors:  L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye
Journal:  Arch Gen Psychiatry       Date:  2011-08-01

2.  Antipsychotic-like effects of a neurotensin receptor type 1 agonist.

Authors:  Chelsea A Vadnie; Jennifer Ayers-Ringler; Alfredo Oliveros; Osama A Abulseoud; Sun Choi; Mario J Hitschfeld; Doo-Sup Choi
Journal:  Behav Brain Res       Date:  2016-02-22       Impact factor: 3.332

3.  Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders.

Authors:  Leah H Rubin; C Sue Carter; Jeffrey R Bishop; Hossein Pournajafi-Nazarloo; Lauren L Drogos; S Kristian Hill; Anthony C Ruocco; Sarah K Keedy; James L Reilly; Matcheri S Keshavan; Godfrey D Pearlson; Carol A Tamminga; Elliot S Gershon; John A Sweeney
Journal:  Schizophr Bull       Date:  2014-03-11       Impact factor: 9.306

Review 4.  Neurobiology of sociability.

Authors:  Heather K Caldwell
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

5.  Effects of neurotensin-2 receptor deletion on sensorimotor gating and locomotor activity.

Authors:  David Feifel; Zhen Pang; Zheng Pang; Paul D Shilling; Gilia Melendez; Rudy Schreiber; Donald Button
Journal:  Behav Brain Res       Date:  2010-04-21       Impact factor: 3.332

Review 6.  Promise and pitfalls of animal models of schizophrenia.

Authors:  David Feifel; Paul D Shilling
Journal:  Curr Psychiatry Rep       Date:  2010-08       Impact factor: 5.285

7.  The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance.

Authors:  David Feifel; Gilia Melendez; Rachel J Murray; Dan N Tina Tran; Michelle A Rullan; Paul D Shilling
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

8.  The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle.

Authors:  Paul D Shilling; David Feifel
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

Review 9.  Developing translational animal models for symptoms of schizophrenia or bipolar mania.

Authors:  M A Geyer
Journal:  Neurotox Res       Date:  2008-08       Impact factor: 3.911

10.  The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.

Authors:  D Feifel; S Mexal; Gilia Melendez; Philip Y T Liu; Joseph R Goldenberg; Paul D Shilling
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.